|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Age-related alterations in skeletal metabolism--24-hr whole-body retention of diphosphonate in 250 normal subjects:concise communication显示文摘 | Fogelman I Bessent R | 2002 | J Nucl Med2002，23，4： | 1 |
| 2 | Peripheral and central measurements of bone mineral density are equal y strongly associated with clinical risk factors for osteoporosis显示文摘 | Patel R Black GM Fogelman I | | 0，，02： | 1 |
| 3 | Bone mineral densi- ty in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cy- clophosphamide,methotrexate and 5-fluorouracil (CMF)显示文摘 | Fogelman I Blake G Blamey R | 2003 | Osteoporos Int2003，14，12： | 1 |
| 4 | Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns 显示文摘 | Dubnov-Raz G Juurlink DN Fogelman R | 2008 | Pediatrics2008，122，： | 1 |
| 5 | Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebocontrolled trial显示文摘 | Fogelman I Ribot C Smith R | 2000 | J Clin Endocrinol Metab2000，85，5： | 1 |
| 6 | Severe vitamin B12 Deficiency in an infant associated with a maternal deficien- cy and a strict vegetarian diet 显示文摘 | Weiss R Fogelman Y Bennett M | 2004 | J Pediatr Hematol On- eol2004，26，4： | 1 |
| 7 | Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of eyelophospha mide, methotrexate and 5-fluorouracil (CMF) 显示文摘 | Fogelman I Blake GM Blamey R | 2003 | OsteoporosInt2003，14，12： | 1 |
| 8 | Effect of risedronate on the risk of hip fracture in elderly women显示文摘 | McClung MR Geusens P Miller P Zippel H Bensen WG Roux C Adami S Fogelman I Diamond T Eastell R Meunier PJ Wasnich RD Greenwald M Kaufman JM Chesnut CH Reginster JY | 2001 | N Engl J Med2001，34，： | 1 |
| 9 | Bone mineraldensity in premenopausal women treated for node-positiveearly breast cancer with 2 years of goserelin or 6 months ofcyclophosphamide, methotrexate and 5-fluorouracil (CMF)显示文摘 | Fogelman I Blake GM Blarney R | 2003 | Osteoporos Int2003，14，12： | 1 |
| 10 | A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women 显示文摘 | REID IR EASTELL R FOGELMAN I | 2004 | Arch Int Med2004，165，8： | 1 |
| 11 | Risedronate reverses bone loss in postmenopansal women with low bone mass:results from a multinational, double blind, placebo - controlled trail 显示文摘 | Fogelman I Ribot C Smith R | 2000 | J Clin Endocrinol Metab2000，85，18： | 1 |
| 12 | Risedronate reverse bone loss in postmenopaual women with low bone mass: results from a multination, double-blind, placebo-controll trial显示文摘 | Fogelman I Ribot C Smith R | 2000 | J Clin Endocrinol Metab2000，85，5： | 1 |
| 13 | Risedronate reverses bone loss in postmenopausal women with low bone mass:results from a multinational,double-blind,placebo-controlled trial显示文摘 | Fogelman I Ribot C Smith R | 2000 | J Clin Endocrinol Metab2000，85，5： | 1 |
| 14 | Risedronate reverses bone loss in postmenopaual women with low bone mass: results from a multination, double-blind, placebo-controlled trial显示文摘 | Fogelman I Ribot C Smith R | 2000 | J Clin Endocrinol Metab2000，85，5： | 1 |
| 15 | Idiopathic flushing with dysesthesia: treatment with the 585nm pulsed dye laser 显示文摘 | Fogelman JP Stevenson ML Ashinoff R | 2015 | J Clin Aesthet Dermatol2015，8，8： | 1 |
| 16 | Peripheral and central measurements of bone mineral density are equally strongly associated with clinical risk factors for osteoporosis 显示文摘 | PATEL R BLAKE G M FOGELMAN I | 2007 | Calcif Tissue Int2007，80，2： | 1 |
| 17 | Risedronate reverses bone loss in postmenopausal women with low bone mass:results from a multinational,doubled-blind,placebo-controlled trial显示文摘 | Fogelman I Ribot C Smith R | 2000 | J clin Endrocrinol Metab2000，85，： | 1 |
| 18 | Severe vitamin B12 deficiency in an infant associated with a maternal deficiency and a strict vegetarian diet显示文摘 | Weiss R Fogelman Y Bennett M | 2004 | J Pediatr Hematol Oncol2004，26，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员